Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsJoel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
Estimating the term…
This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method if provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
A method for altering an antimicrobial activity of an isolated defensin polypeptide, comprising:
A method of modulating an immune response against a microbe in a subject, comprising:
A method of modulating a cytotoxic activity of a non-ADP-ribosylated or a non-ribosylated defensin polypeptide, comprising contacting the non-ADP-ribosylated or a non-ribosylated defensin polypeptide with an ADP-ribosylated or a ribosylated defensin, thereby modulating the cytotoxic activity of the non-ADP-ribosylated or non-ribosylated defensin.
A method of treating a pulmonary disease or an inflammatory disease in a subject, comprising administering to the subject a therapeutically effective amount of a defensin polypeptide comprising an arginine residue that is modified by ADP-ribosylation or ribosylation, thereby treating the pulmonary disease or the inflammatory disease.
Dependencies are inferred from the claim text.